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To the Editor: Cutaneous squamous cell carcinoma
(SCC) is the second most common nonmelanoma
skin cancer (NMSC) but accounts for the bulk
of deaths from NMSCs due to its capacity to metas-
tasize.1 Although incidence is increasing in the
United States, outcomes data are not reported in
national cancer registries and disease mortality is not
well-described in the literature.2We report theoverall
survival (OS) and progression-free survival (PFS) in
36 patientswith American Joint Committee onCancer
(AJCC) stage IV SCC in this retrospective cohort study
at a large academic center.
The Stanford Cancer Center Research Database
was queried using the terms ‘‘metastatic,’’ ‘‘cuta-
neous,’’ ‘‘SCC,’’ and ‘‘squamous cell carcinoma’’ for
potential cases from 1997 to 2013 following
institutional review board approval. Cases were
included if there was documentation of a cutaneous
primary site and biopsy-proven stage IV disease
under the current AJCC TNM staging guidelines
(7th ed, 2010).3* Clinical and demographic data
were analyzed using STATA 12 (Statacorp LP).
OS and PFS were estimated by Kaplan-Meier
analysis with date of stage IV disease diagnosis as
the start of follow-up. The endpoint for OS was the
all-cause date of death ascertained through
medical records or public records including the
Social Security Death Index; the endpoint for
PFS was the earliest date of disease progression,
defined as development of new metastases,
enlargement of existing tumors, recurrence, or
all-cause death. Patients not meeting the endpoint
before the data cutoff date of October 1, 2014, were
right-censored.
Thirty-six patients met inclusion criteria, of
whom 31 were male and 33 were Caucasian. At the
time of stage IV diagnosis, 14 had M1, 23 had N2/N3,ª2015by theAmericanAcademyofDermatology, Inc. Publishedby
Elsevier, Inc. This is an open access article under theCCBY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
*To qualify as Stage IV, there must be evidence of distant
metastasis (M1) and/or involvement of at least 1 lymph node
measuring at least 3 cm (N2 or N3) and/or direct tumor
extension into the bony skeleton or perineural invasion of the
skull base (T4).
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10 patients during follow-up. The most common
primary sites were head (n ¼ 23), upper
extremities (n ¼ 4), and lower extremities, neck,
and trunk (n ¼ 1 for each). The most common
metastatic sites were lymph nodes (n ¼ 21), parotid
gland (n ¼ 12), and soft tissue (n ¼ 5). Nine patients
were immunosuppressed at the time of stage IV
diagnosis.
Following stage IV diagnosis, treatment types
received were as follows: adjuvant radiation
(n ¼ 22), surgery (n ¼ 19), chemotherapy (n ¼ 18),
and radiation (n ¼ 17). The median (interquartile
range) follow-up period was 1.87 (0.71-3.65) years,
during which 26 patients died.
The median OS was 2.19 (95% confidence
interval [CI] 1.72-4.04; range 0.22-12.09) years and
the median PFS was 0.67 (95% CI 0.54-1.03; range
0.06-12.09) years (Fig 1). The 5-year OS rate was
26% (95% CI 12%-43%). In Cox proportional
hazard models, N2/N3 stage at diagnosis was
significantly associated with worse OS (hazard ratio
2.81; 95% CI 1.17-6.77) and worse PFS (hazard ratio
2.31; 95% CI 1.04-5.16) compared with N0/N1 stage.
Additionally, M1 stage at diagnosis or during
follow-up was not associated with worse OS
(hazard ratio 1.48; 95% CI 0.61-3.56) or worse PFS
(hazard ratio 1.21; 95% CI 0.57-2.60) compared
with M0 stage, likely due to an inadequate sample
size.
Neither immunosuppression nor AJCC T stage at
diagnosis was associated with OS or PFS at P\ .05
level. Treatment types (surgery, chemotherapy,
radiation, adjuvant radiation) did not significantly
alter OS or PFS. It is possible that current treatment
modalities do not make a significant difference in OS
or PFS or that the sample size was not large enough
to detect such a difference.
Our study provides a prognostic baseline for
patients with AJCC stage IV SCC. The 5-year OS
rate of 26% is comparable to the OS rate from an
Australian study focused on M1 SCC, reported at
11%,* and is improved comparedwith data on N1-N3
SCC (80%).4 Our findings await validation by larger
multicenter studies of patients staged under the AJCC
7th edition guidelines.3
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Fig 1. Overall survival and progression-free survival of AJCC stage 4 squamous cell carcinoma.
Kaplan-Meier curves with associated 95% confidence intervals for overall survival (A) and
progression-free survival (B) are shown with vertical ticks denoting censored data. The number
of patients at risk at each major time point is provided below the plots.
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hypo-fractionated radiotherapy: A
retrospective analysis in 117 elderly patients
To the Editor: Radiotherapy (RT) is an option for
facial basal cell carcinomas. The optimum dose and
fraction remain to be clearly defined, but the
numerous treatment fractions required by the
most common radiotherapy regimens1 may render
RT impractical in frail patients unfit for daily
irradiation.
After successfully submitting a small number of
patients to palliative treatment with once-weekly
administrations (5 Gy per week up to 25-30 Gy), we
extended this schedule to a larger population of frail
patients.
From February 2007 to May 2010, frail elderly
outpatients with basal cell carcinoma (BCC) (Table I)
were treated with the once-weekly schedule and
then evaluated for inclusion in this retrospective
review. Frailty characteristics were evaluated using
the Katz functionality index2 (Table I) and the
Charlson age-factored comorbidity index.3 All
patients (n ¼ 117) had a Katz functionality index
less than 6 and 98 of 117 had a Charlson age-factored
comorbidity index greater than 5 with lesions
requiring a complex reconstruction (Fig 1). The
remaining 19 patients refused surgery. Patients with
T3/T4 lesions (3 patients) or receiving re-irradiations
(4 patients) were excluded because they usually
underwent various palliative regimens tailored to
their specific conditions. Fully informed, written
consent was required. The response was assessed
by means of physical examination (documented by
standardized digital photography) at 4 and 8 weeks
after final radiation treatment.
